Cipla Ltd (CIPLA)
₹1,378.90
Mkt cap
₹1.11L Cr
P/E ratio
35.90
P/B
3.15
Div yield
0.94%
ROE
11.60%
ROCE
15.50%
EPS (TTM)
₹38.41
Book value
₹438
52W range
1,166–1,625
Sector
Healthcare
Price history
Previous close
Incorporated in 1935, Cipla Ltd is in the business of manufacturing, developing, and marketing a wide range of branded and generic formulations and APIs [1]
NSE CIPLABSE 500087
Health check
Constructive
ValuationFair
ProfitabilityAverage
GrowthModerate
TechnicalsBullish
52-week range
−15.15% from high₹1,379
₹1,166+18.29% from low₹1,625
Current
₹1,378.90
Prev close
₹1,358.00
Day
+1.54%
Price performance
1D
+1.54%
1W
+3.06%
1M
−0.03%
3M
−5.97%
6M
+4.65%
1Y
−16.18%
YTD
−8.78%
Financials
Revenue, profit & margin
P/E ratio
35.9×
CIPLA is 4% above the sector median of 34.4×
CIPLA35.9×
Sector median34.4×
| Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 | Sep 2026 | Trend | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 6,678 | 6,604 | 6,163 | 6,694 | 7,051 | 7,073 | 6,730 | 6,957 | 7,589 | 7,074 | 6,541 | 7,119 | 7,404 | |
| Expenses | 4,944 | 4,856 | 4,847 | 4,978 | 5,165 | 5,084 | 5,192 | 5,179 | 5,695 | 5,819 | 5,586 | 5,927 | 6,016 | |
| Operating Profit | 1,734 | 1,748 | 1,316 | 1,716 | 1,886 | 1,989 | 1,538 | 1,778 | 1,895 | 1,255 | 955 | 1,192 | 1,388 | |
| OPM % | 26% | 26% | 21% | 26% | 27% | 28% | 23% | 26% | 25% | 18% | 15% | 17% | 19% | |
| Other Income | 176 | -10 | 249 | 160 | 191 | 222 | 289 | 259 | 269 | -70 | 148 | 211 | 151 | |
| Interest | 26 | 30 | 18 | 18 | 15 | 15 | 14 | 14 | 13 | 14 | 13 | 17 | 17 | |
| Depreciation | 290 | 233 | 288 | 247 | 272 | 280 | 309 | 253 | 297 | 278 | 383 | 304 | 345 | |
| Profit before tax | 1,594 | 1,474 | 1,259 | 1,611 | 1,789 | 1,916 | 1,504 | 1,770 | 1,854 | 893 | 707 | 1,082 | 1,177 | |
| Tax % | 28% | 28% | 26% | 27% | 27% | 17% | 19% | 27% | 27% | 24% | 22% | 27% | 27% | |
| Net Profit | 1,155 | 1,068 | 932 | 1,175 | 1,305 | 1,575 | 1,214 | 1,292 | 1,353 | 674 | 543 | 786 | 852 | |
| EPS in Rs | 14.01 | 13.08 | 11.63 | 14.58 | 16.13 | 19.45 | 15.13 | 16.06 | 16.73 | 8.37 | 6.87 | 9.77 | 10.86 | |
| Raw PDF |
Earnings
Results dates & reactionsNo upcoming results date on calendar.
Fresh quarters land in the Financials table above, tagged NSE until screener catches up.
Avg earnings-day move −0.15% · closed higher next day 23 of last 63
| Q3FY24 | Q4FY24 | Q1FY25 | Q2FY25 | Q3FY25 | Q4FY25 | Q1FY26 | Q2FY26 | Q3FY26 | Q4FY26 | Q1FY27 | Q2FY27 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Broadcast | 22 Jan '24◦ | 11 May '24◦ | 26 Jul '24◦ | 29 Oct '24◦ | 29 Jan '25 | 13 May '25◦ | 25 Jul '25 | 30 Oct '25 | 23 Jan '26 | 13 May '26 | 23 Jul '26 | 27 Oct '26 |
| Earnings day | +7.05% | +5.61% | −1.34% | −4.01% | +0.24% | −1.66% | +3.00% | −2.59% | −4.04% | +2.73% | −1.56% | +1.16% |
| +1 day | +7.68% | +1.33% | −2.93% | +5.02% | +2.59% | −1.18% | +5.65% | −5.05% | −4.19% | +11.17% | −0.32% | +0.59% |
| +5 days | +2.64% | +4.82% | −3.81% | +6.67% | +2.00% | −2.48% | +1.00% | −4.77% | −4.29% | +8.30% | +3.63% | — |
| +15 days | +8.29% | +8.42% | −0.77% | +1.74% | +4.33% | −3.17% | +5.20% | −4.38% | −1.02% | +8.23% | +3.09% | — |
| +30 days | +12.84% | +11.96% | +3.62% | −1.97% | +2.37% | −0.66% | +4.28% | −4.03% | −2.69% | +11.44% | −1.44% | — |
| Filing | XBRL | XBRL | XBRL | XBRL | XBRL | XBRL | XBRL | XBRL | XBRL |
Corporate actions
Last 6 months| Kind | Value | Ex-date | Record |
|---|---|---|---|
| dividend Dividend - Rs 13 Per Share | 13.00 | 5 Jun '26 | 5 Jun '26 |
Shareholding
as of Sep 202629.20%Promoter
Promoters29.20%0.02
FIIs20.24%0.04
DIIs34.61%0.26
Public15.60%0.33
Government0.33%0.05
Ownership trend
Peers
7 companiesValuation vs quality
P/E × ROCE · bubble = market cap| Name | CMP | P/E | Mkt Cap | Div Yld | NP Qtr | Qtr Profit Var | Sales Qtr | Qtr Sales Var | ROCE |
|---|---|---|---|---|---|---|---|---|---|
| Sun Pharma.Inds. | ₹1,777.70 | 34.63 | 4,26,058 | 0.90% | 1,995 | −10.53% | 16,199 | +11.88% | 20.53% |
| Divi's Lab. | ₹9,780.00 | 87.14 | 2,59,628 | 0.31% | 902 | +65.50% | 3,080 | +27.80% | 21.97% |
| Torrent Pharma. | ₹4,613.40 | 81.11 | 1,76,090 | 0.82% | 534 | −10.03% | 4,979 | +50.79% | 15.19% |
| Laurus Labs | ₹2,405.50 | 96.96 | 1,29,914 | 0.08% | 436 | +126.43% | 2,206 | +33.44% | 17.76% |
| Zydus Lifesci. | ₹1,245.50 | 25.52 | 1,24,239 | 0.08% | 990 | −35.09% | 8,017 | +21.96% | 21.14% |
| Dr Reddy's Labs | ₹1,352.00 | 40.30 | 1,12,849 | 0.59% | 913 | −31.35% | 8,698 | −1.48% | 13.04% |
| Cipla | ₹1,378.90 | 35.87 | 1,11,397 | 0.94% | 852 | −35.05% | 7,404 | −2.44% | 15.49% |
| Median: 158 Co. | ₹426.38 | 34.42 | 1,919 | 0.08% | 14 | +22.08% | 175 | +18.92% | 15.12% |
Filings
Annual reports15
Concall transcripts109
TranscriptOct 2026PPTOct 2026RECOct 2026TranscriptJul 2026PPTJul 2026RECJul 2026TranscriptMay 2026PPTMay 2026RECMay 2026TranscriptJan 2026PPTJan 2026RECJan 2026TranscriptNov 2025PPTNov 2025RECNov 2025TranscriptJul 2025PPTJul 2025RECJul 2025TranscriptMay 2025PPTMay 2025TranscriptFeb 2025PPTFeb 2025PPTJan 2025TranscriptNov 2024
Credit ratings6
Announcements5
Announcement under Regulation 30 (LODR)-Earnings Call Transcript 30 OctAnnouncement under Regulation 30 (LODR)-Allotment of ESOP / ESPS 29 Oct - In compliance with the provisions of Regulation 30 of SEBI (LODR) Regulations, 2015, we hereby notify that the Operations and Administrative Committee of the Company …Announcement under Regulation 30 (LODR)-Newspaper Publication 28 Oct - Newspaper intimation for financial results for the quarter and half year ended 30th September, 2026.Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome 27 Oct - Audio recording of earnings call for quarter and half year ended 30 September 2026 posted online.Grant Of Employee Stock Options And Employee Stock Appreciation Rights 27 Oct - Cipla granted 8,679 stock options and 27,140 ESARs on 27 October 2026.